Research
Hormonal
GLP-1 receptor agonists lower blood pressure through central sympathetic inhibition, natriuresis, and improved endothelial function, with effects largely independent of weight loss.
GLP-1 drugs (like Ozempic or Wegovy) lower blood pressure through multiple pathways: they calm the nervous system's stress response, help kidneys excrete salt, and improve blood vessel health. This happens even before significant weight loss occurs.
GoodSupportsHIGH confidence
GLP-1 RAs lower BP through mechanisms that are distinctively neurohormonal and metabolic... These mechanisms operate independently of weight change... GLP-1 RAs act on important brain stem structures... to reduce central sympathetic outflow
Why this rating
Supported by CVOTs (LEADER, SUSTAIN) and mechanistic studies.
Source
Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data
Andrej Belančić et al. · British Journal of Clinical Pharmacology · 2025
DOI 10.1002/bcp.70378
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →